IN2014KN02915A - - Google Patents

Info

Publication number
IN2014KN02915A
IN2014KN02915A IN2915KON2014A IN2014KN02915A IN 2014KN02915 A IN2014KN02915 A IN 2014KN02915A IN 2915KON2014 A IN2915KON2014 A IN 2915KON2014A IN 2014KN02915 A IN2014KN02915 A IN 2014KN02915A
Authority
IN
India
Prior art keywords
compounds
bacterial
effective
methylta
naphthyndin
Prior art date
Application number
Other languages
English (en)
Inventor
John J Partridge
John Colucci
Yves Gareau
Michel Therien
Robert Zamboni
Barry Hafkin
Anthony Marfat
Helmi Zaghdane
Original Assignee
Debiopharm Int Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Int Sa filed Critical Debiopharm Int Sa
Publication of IN2014KN02915A publication Critical patent/IN2014KN02915A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN2915KON2014 2012-06-19 2013-06-19 IN2014KN02915A (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661559P 2012-06-19 2012-06-19
PCT/IB2013/001780 WO2013190384A1 (en) 2012-06-19 2013-06-19 Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide

Publications (1)

Publication Number Publication Date
IN2014KN02915A true IN2014KN02915A (no) 2015-05-08

Family

ID=49768192

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2915KON2014 IN2014KN02915A (no) 2012-06-19 2013-06-19

Country Status (34)

Country Link
US (2) US8901105B2 (no)
EP (1) EP2861608B8 (no)
JP (2) JP6085026B2 (no)
KR (1) KR101720885B1 (no)
CN (1) CN104684922B (no)
AU (1) AU2013279021C1 (no)
BR (2) BR112014031635B1 (no)
CA (1) CA2875916C (no)
CL (1) CL2014003472A1 (no)
CY (1) CY1122006T1 (no)
DK (1) DK2861608T3 (no)
EA (1) EA028136B1 (no)
ES (1) ES2731474T3 (no)
HK (1) HK1208226A1 (no)
HR (1) HRP20190980T1 (no)
HU (1) HUE043836T2 (no)
IL (1) IL236066A (no)
IN (1) IN2014KN02915A (no)
LT (1) LT2861608T (no)
MA (1) MA37625B1 (no)
ME (1) ME03392B (no)
MX (1) MX356695B (no)
MY (1) MY170437A (no)
NZ (1) NZ702695A (no)
PH (1) PH12014502823A1 (no)
PL (1) PL2861608T3 (no)
PT (1) PT2861608T (no)
RS (1) RS58898B1 (no)
SG (1) SG11201408100YA (no)
SI (1) SI2861608T1 (no)
TN (1) TN2014000506A1 (no)
TR (1) TR201909016T4 (no)
UA (1) UA113215C2 (no)
WO (1) WO2013190384A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5468899B2 (ja) 2006-07-20 2014-04-09 アフィニウム ファーマシューティカルズ， インク． Ｆａｂｉインヒビターとしてのアクリルアミド誘導体
CN104684922B (zh) 2012-06-19 2016-10-26 德彪药业国际股份公司 (e)-n-甲基-n-((3-甲基苯并呋喃-2-基)甲基)-3-(7-氧代-5,6,7,8-四氢-1,8-萘啶-3-基)丙烯酰胺的前药衍生物
JP6998881B2 (ja) * 2016-02-26 2022-02-10 デビオファーム・インターナショナル・エス・アー 糖尿病性足感染症の処置のための医薬
WO2018048882A1 (en) 2016-09-06 2018-03-15 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
TWI762706B (zh) 2017-08-24 2022-05-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
WO2019177975A1 (en) * 2018-03-12 2019-09-19 The Board Of Trustees Of The University Of Illinois Antibiotics effective for gram-negative pathogens
US20230035837A1 (en) 2018-11-12 2023-02-02 Debiopharm International S.A. Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
WO2020132174A1 (en) 2018-12-21 2020-06-25 Acurx Pharmaceuticals, Llc Dna polymerase iiic inhibitors and use thereof
EA202192246A1 (ru) 2019-02-14 2021-11-18 Дебиофарм Интернэшнл C.A. Состав с афабицином, способ его получения и его применение
BR112021025306A8 (pt) * 2019-06-14 2022-09-20 Debiopharm Int Sa Medicamento e seu uso para o tratamento de infecções bacterianas envolvendo biofilme
US20230159519A1 (en) 2019-12-19 2023-05-25 Debiopharm International S.A. Novel compounds and their use
US20230093542A1 (en) 2020-02-18 2023-03-23 Novo Nordisk A/S Glp-1 compositions and uses thereof
BR112023027268A2 (pt) 2021-06-23 2024-04-30 Debiopharm Int Sa Compostos inovadores e seu uso

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3828068A (en) 1971-05-10 1974-08-06 Tenneco Chem ((substituted indazolyl)-n1-methyl)carbamates
US4154943A (en) 1977-12-29 1979-05-15 University Of Vermont Preparation of vincadifformine
FR2619111B1 (fr) 1987-08-07 1991-01-11 Synthelabo Derives de (piperidinyl-4)methyl-2 tetrahydro-1,2,3,4 9h-pyrido (3,4-b) indole, leur preparation et leur application en therapeutique
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
DE4126662A1 (de) 1991-08-13 1993-02-18 Boehringer Mannheim Gmbh Neue 3,5-di-tert.butyl-4-hydroxyphenyl-derivate, verfahren zu ihrer herstellung und arzneimittel
HU210679B (en) 1991-11-21 1995-06-28 Richter Gedeon Vegyeszet Process for producing new tetrahydro-pyrido/3,4-b/indol derivatives and pharmaceutical compositions containing the same
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5416193A (en) 1993-04-30 1995-05-16 Pfizer Inc. Coupling reagent and method
MA23420A1 (fr) 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
US5614551A (en) 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents
CA2193966A1 (en) 1994-06-29 1996-01-11 Fadia El-Fehail Ali Vitronectin receptor antagonists
US6176842B1 (en) 1995-03-08 2001-01-23 Ekos Corporation Ultrasound assembly for use with light activated drugs
US5989832A (en) 1995-04-21 1999-11-23 Microcide Pharmaceuticals, Inc. Method for screening for non-tetracycline efflux pump inhibitors
JPH11506429A (ja) 1995-05-11 1999-06-08 ビオヘミー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 抗細菌セファロスポリン類
US6057291A (en) 1995-06-02 2000-05-02 University Of British Columbia Antimicrobial cationic peptides
DE69712332T2 (de) 1996-02-29 2002-10-02 Fujisawa Pharmaceutical Co Beta-lactam-antibiotikum enthaltende tabletten und verfahren zu deren herstellung
US6239154B1 (en) 1996-03-08 2001-05-29 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US6367985B1 (en) 1996-03-12 2002-04-09 Intellectual Property Company Optical connector using large diameter alignment features
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US6451816B1 (en) 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
US6503881B2 (en) 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6995254B1 (en) 1996-08-28 2006-02-07 Affinium Pharmaceuticals, Inc. Polynucleotide encoding the enoyl-acyl carrier protein reductase of Staphylococcus aureus, FAB I
NZ334883A (en) 1996-09-20 2000-09-29 Meiji Seika Kaisha A crystalline substance of cefditoren pivoxil which has desirable thermal storage stability and the production of the same
US6521408B1 (en) 1997-09-25 2003-02-18 National Institute Of Agrobiological Sciences Method for assessing a function of a gene
DE19641437A1 (de) 1996-10-08 1998-04-09 Basf Ag 1,3-Bis-(N-lactamyl)propane und deren pharmazeutische und kosmetische Verwendung
DE19652239A1 (de) 1996-12-16 1998-06-18 Bayer Ag Verwendung von 7-(2-Oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-chinolon- und -naphthyridoncarbonsäure-Derivaten zur Therapie von Helicobacter-pylori-Infektionen und den damit assoziierten gastroduodenalen Erkrankungen
SI9600371B (sl) 1996-12-18 2005-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Etilidenski derivati tricikličnih karbapenemov
AU6870098A (en) 1997-03-31 1998-10-22 Du Pont Merck Pharmaceutical Company, The Indazoles of cyclic ureas useful as hiv protease inhibitors
PT971735E (pt) 1997-04-01 2008-06-02 Borody Thomas J Métodos e composições para tratamento de doença inflamatória do intestino
US6406880B1 (en) 1997-05-02 2002-06-18 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
US6184363B1 (en) 1997-06-13 2001-02-06 Northwestern University Inhibitors of β-lactamases and uses therefor
US6207679B1 (en) 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
EP0995746A1 (en) 1997-06-23 2000-04-26 Yoshitomi Pharmaceutical Industries, Ltd. Prophylactic or therapeutic agent for diseases attributable to infection with helicobacters
AUPO758297A0 (en) 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome
US6198000B1 (en) 1997-07-07 2001-03-06 Pfizer Inc. Intermediates useful in the synthesis of quinoline antibiotics
AU737018B2 (en) 1997-07-25 2001-08-09 Tsumura & Co. Pyridylacrylamide derivatives and nephritis remedies and TGF-beta inhibitors containing the same
HN1998000106A (es) 1997-08-01 1999-01-08 Pfizer Prod Inc Composiciones parenterales de alatroflaxacino
US5932743A (en) 1997-08-21 1999-08-03 American Home Products Corporation Methods for the solid phase synthesis of substituted indole compounds
GB9717804D0 (en) 1997-08-22 1997-10-29 Zeneca Ltd Chemical compounds
US6432444B1 (en) 1997-10-31 2002-08-13 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymes for treating dermatological infections
DE19881833B4 (de) 1997-10-31 2007-05-10 Syngenta Participations Ag Transgene Pflanzen
CN1285823A (zh) 1997-11-07 2001-02-28 先灵公司 作为h3受体拮抗剂的苯基－烷基－咪唑
SE9704404D0 (sv) 1997-11-28 1997-11-28 Astra Ab New compounds
GB9725244D0 (en) 1997-11-29 1998-01-28 Zeneca Ltd Chemical compounds
DE19753298A1 (de) 1997-12-01 1999-06-02 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
ID25469A (id) 1998-01-07 2000-10-05 Meiji Seika Kaisha Komposisi sefalosporin amorf yang stabil secara kristalografi dan proses pembuatannya
US6184380B1 (en) 1999-01-25 2001-02-06 Pfizer Inc. Process for preparing naphthyridones and intermediates
US6248343B1 (en) 1998-01-20 2001-06-19 Ethicon, Inc. Therapeutic antimicrobial compositions
PA8466701A1 (es) 1998-01-21 2000-09-29 Pfizer Prod Inc Comprimido de mesilato de trovafloxacino
US6204279B1 (en) 1998-06-03 2001-03-20 Microcide Pharmaceuticals, Inc. Peptidomimetic efflux pump inhibitors
RU2241489C2 (ru) 1998-02-27 2004-12-10 Биора Биоэкс Аб Композиции матриксных протеинов для залечивания ран
US6350738B1 (en) 1998-03-06 2002-02-26 Brigham Young University Steroid derived antibiotics
US6369049B1 (en) 1998-04-30 2002-04-09 Eli Lilly And Company Treatment of mastitis
DE19820801A1 (de) 1998-05-09 1999-11-25 Gruenenthal Gmbh Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten
DE19821039A1 (de) 1998-05-11 1999-11-18 Bayer Ag Verfahren zur Herstellung von (S,S)-Benzyl-2,8-diazabicyclo[4.3.0]nonan
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
US6428579B1 (en) 1998-07-01 2002-08-06 Brown University Research Foundation Implantable prosthetic devices coated with bioactive molecules
US6423741B1 (en) 1998-07-10 2002-07-23 Council Of Scientific And Industrial Research Anti-microbial composition and method for producing the same
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
KR100412231B1 (ko) 1998-08-04 2003-12-24 다께다 쉐링 플라우 애니멀 헬스 가부시키가이샤 β-락탐 항생물질의 안정화제제
TW537895B (en) 1998-08-21 2003-06-21 Senju Pharma Co Aqueous solution preparation containing gatifloxacin
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US6518487B1 (en) 1998-09-23 2003-02-11 Pioneer Hi-Bred International, Inc. Cyclin D polynucleotides, polypeptides and uses thereof
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
DE19851104C2 (de) 1998-11-06 2003-04-03 Huhtamaki Forchheim Verfahren zum Herstellen eines mehrschichtigen Verbundes
TW526202B (en) 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
JP4819223B2 (ja) 1999-02-18 2011-11-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 発光マーカーとして使用するためのフタルアミド−ランタニド錯体
US6235728B1 (en) 1999-02-19 2001-05-22 Bristol-Myers Squibb Company Water-soluble prodrugs of azole compounds
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2000052035A1 (en) 1999-03-03 2000-09-08 Princeton University Bacterial transglycosylases: assays for monitoring the activity using lipid ii substrate analogs and methods for discovering new antibiotics
US6495161B1 (en) 1999-03-09 2002-12-17 Vivorx, Inc. Cytoprotective biocompatible containment systems for biologically active materials and methods of making same
US6224579B1 (en) 1999-03-31 2001-05-01 The Trustees Of Columbia University In The City Of New York Triclosan and silver compound containing medical devices
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
JP2003502282A (ja) 1999-04-08 2003-01-21 ザ ゼネラル ホスピタル コーポレーション ヒト転移性細胞の作用因子源から離れた意図された移動
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
US6290946B1 (en) 1999-05-13 2001-09-18 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders and antibacterial agents
US6514535B2 (en) 1999-05-21 2003-02-04 Noveon Ip Holdings Corp. Bioadhesive hydrogels with functionalized degradable crosslinks
AR024077A1 (es) 1999-05-25 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
CO5370679A1 (es) 1999-06-01 2004-02-27 Smithkline Beecham Corp Inhibidores fab 1
US6239141B1 (en) 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions
CO5180605A1 (es) 1999-06-23 2002-07-30 Smithkline Beecham Corp Compuestos de indol
CA2282066C (en) 1999-06-29 2010-09-07 Smithkline Beecham Corporation Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6346391B1 (en) 1999-07-22 2002-02-12 Trustees Of Tufts College Methods of reducing microbial resistance to drugs
ES2221624T3 (es) 1999-08-26 2005-01-01 Ganeden Biotech, Inc. Uso de aceite de emu como vehiculo para mediaciones antifungicas, antibacterianas y antiviricas.
US6221859B1 (en) 1999-08-27 2001-04-24 Merck & Co., Inc. Carbapenem antibacterial compositions and methods of the treatment
US6174878B1 (en) 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
EP1212091B1 (en) 1999-09-11 2007-02-28 The Procter & Gamble Company Polyoxyalkylene copolymers containing pourable liquid vehicles
CA2351673A1 (en) 1999-09-17 2001-03-29 Suntory Limited Pharmaceutical antibacterial compositions
US6500463B1 (en) 1999-10-01 2002-12-31 General Mills, Inc. Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles
WO2001027103A1 (en) 1999-10-08 2001-04-19 Smithkline Beecham Corporation Fab i inhibitors
US6730684B1 (en) 1999-10-08 2004-05-04 Affinium Pharmaceuticals, Inc. Fab I inhibitors
US6762201B1 (en) 1999-10-08 2004-07-13 Affinium Pharmaceuticals, Inc. Fab I inhibitors
WO2001026652A1 (en) 1999-10-08 2001-04-19 Smithkline Beecham Corporation Fab i inhibitors
EP1225895B1 (en) 1999-10-08 2005-05-04 Affinium Pharmaceuticals, Inc. Fab i inhibitors
CA2323008C (en) 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
DE60014143T2 (de) 1999-10-19 2006-03-02 Sato Pharmaceutical Co., Ltd. Antimikrobielle 4-oxochinolizine mit 2-pyridongerüsten als teilstruktur
US6951729B1 (en) 1999-10-27 2005-10-04 Affinium Pharmaceuticals, Inc. High throughput screening method for biological agents affecting fatty acid biosynthesis
DE60025019T2 (de) 1999-10-29 2006-08-24 Nektar Therapeutics, San Carlos Trockenpulverzusammensetzungen mit verbesserter dispersivität
US6531291B1 (en) 1999-11-10 2003-03-11 The Trustees Of Columbia University In The City Of New York Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof
US6514986B2 (en) 2000-11-22 2003-02-04 Wockhardt Limited Chiral fluoroquinolone arginine salt forms
US6656703B1 (en) 1999-12-29 2003-12-02 Millennium Pharamaceuticals, Inc. High throughput screen for inhibitors of fatty acid biosynthesis in bacteria
US6372752B1 (en) 2000-02-07 2002-04-16 Genzyme Corporation Inha inhibitors and methods of use thereof
ES2179729B1 (es) 2000-03-23 2003-12-16 Dreiman Lab Farmaceuticos S A Forma farmaceutica solida de administracion oral dispersable en agua, que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica.
US6514541B2 (en) 2000-03-28 2003-02-04 Council Of Scientific And Industrial Research Formulation comprising thymol useful in the treatment of drug resistant bacterial infections
JP2003531184A (ja) 2000-04-21 2003-10-21 ローディア／カイレックス・インコーポレイテッド （ｒ）−１−（アリールオキシ）プロパン−２−オールの製造方法
AU2001282988B2 (en) 2000-07-26 2006-01-05 Atopic Pty Ltd Methods for treating atopic disorders
DE10037029A1 (de) 2000-07-27 2002-02-28 Kugelstrahlzentrum Aachen Gmbh Verfahren und Vorrichtung zum Umformen von Strukturbauteilen
US6288239B1 (en) 2000-09-19 2001-09-11 Board Of Trustees Operating Michigan State University 5-trityloxymethyl-oxazolidinones and process for the preparation thereof
AU2001290068B2 (en) 2000-09-21 2006-03-02 Cambridge Semiconductor Limited Semiconductor device and method of forming a semiconductor device
US7048926B2 (en) 2000-10-06 2006-05-23 Affinium Pharmaceuticals, Inc. Methods of agonizing and antagonizing FabK
US6821746B2 (en) 2000-10-06 2004-11-23 Affinium Pharmaceuticals, Inc. Methods of screening for FabK antagonists and agonists
CA2428191A1 (en) 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
US20020107266A1 (en) 2000-12-12 2002-08-08 Marguerita Lim-Wilby Compounds, compositions and methods for treatment of parasitic infections
US6388070B1 (en) 2001-01-05 2002-05-14 Orchid Chemicals & Pharmaceuticals Ltd. Thioester derivatives of thiazolyl acetic acid and their use in the preparation of cephalosporin compounds
US6495158B1 (en) 2001-01-19 2002-12-17 Lec Tec Corporation Acne patch
PA8539401A1 (es) 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
JP4387804B2 (ja) 2001-04-06 2009-12-24 アフィニアム・ファーマシューティカルズ・インコーポレイテッド ＦａｂＩ阻害剤
US6503906B1 (en) 2002-02-21 2003-01-07 Ren-Jin Lee Method for optimizing ciprofloxacin treatment of anthrax-exposed patients according to the patient's characteristics
CN1655783A (zh) 2002-04-02 2005-08-17 株式会社津村 含有吡啶丙烯酰胺衍生物的磷酸二酯酶iv抑制剂
AU2003250475A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors
SI1575951T1 (sl) 2002-12-06 2014-10-30 Debiopharm International Sa Forum "Apres-Demain" Heterociklične spojine, postopki za njihovo izdelavo in njihova uporaba v terapiji
DE602004016831D1 (de) 2003-03-17 2008-11-13 Affinium Pharm Inc Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
JP5087406B2 (ja) 2004-06-04 2012-12-05 アフィニウム ファーマシューティカルズ， インク． 治療薬ならびにその製造方法および使用方法
CA2591948C (en) 2005-01-19 2013-11-12 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
CN101415701A (zh) * 2005-12-05 2009-04-22 Affinium医药公司 作为fabi抑制剂的杂环丙烯酰胺化合物和抗菌剂
US20090156578A1 (en) 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
JP5468899B2 (ja) 2006-07-20 2014-04-09 アフィニウム ファーマシューティカルズ， インク． Ｆａｂｉインヒビターとしてのアクリルアミド誘導体
ATE540041T1 (de) 2006-11-21 2012-01-15 Rigel Pharmaceuticals Inc Prodrug-salze von 2,4-pyrimidindiaminverbindungen und anwendungen davon
US8263613B2 (en) 2007-02-16 2012-09-11 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab I inhibitors
WO2009003136A1 (en) 2007-06-26 2008-12-31 Rigel Pharmaceuticals, Inc. Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
EP2445343B1 (en) * 2009-06-25 2021-08-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
US8431576B2 (en) * 2009-06-25 2013-04-30 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
UA108077C2 (xx) 2009-07-02 2015-03-25 Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну
US8846711B2 (en) 2009-11-18 2014-09-30 Fab Pharma S.A.S. Heterocyclic acrylamides and their use as pharmaceuticals
EP2579863A4 (en) 2010-06-11 2013-11-27 Affinium Pharm Inc COMPOUNDS FOR THE TREATMENT OF BOVINE MASTITIS
CN102675311A (zh) 2011-06-14 2012-09-19 苏春华 一种氟代丙烯酰胺的衍生物
SG11201402409UA (en) 2011-12-02 2014-10-30 Aurigene Discovery Tech Ltd Substituted pyridine derivatives as fabi inhibitors
CN104684922B (zh) 2012-06-19 2016-10-26 德彪药业国际股份公司 (e)-n-甲基-n-((3-甲基苯并呋喃-2-基)甲基)-3-(7-氧代-5,6,7,8-四氢-1,8-萘啶-3-基)丙烯酰胺的前药衍生物

Also Published As

Publication number Publication date
AU2013279021A1 (en) 2015-01-22
US10035813B2 (en) 2018-07-31
KR20150023779A (ko) 2015-03-05
EP2861608A1 (en) 2015-04-22
PL2861608T3 (pl) 2019-09-30
CL2014003472A1 (es) 2015-07-31
MY170437A (en) 2019-07-31
CN104684922B (zh) 2016-10-26
CN104684922A (zh) 2015-06-03
ME03392B (me) 2020-01-20
MA37625B1 (fr) 2017-04-28
RS58898B1 (sr) 2019-08-30
EP2861608B8 (en) 2019-06-19
MX356695B (es) 2018-06-11
US20140051666A1 (en) 2014-02-20
IL236066A0 (en) 2015-02-01
CA2875916C (en) 2017-04-25
TR201909016T4 (tr) 2019-07-22
TN2014000506A1 (en) 2016-03-30
MA37625A1 (fr) 2016-09-30
US20150065415A1 (en) 2015-03-05
PH12014502823B1 (en) 2015-02-02
UA113215C2 (xx) 2016-12-26
IL236066A (en) 2016-12-29
EP2861608A4 (en) 2016-01-20
LT2861608T (lt) 2019-07-10
ES2731474T3 (es) 2019-11-15
WO2013190384A1 (en) 2013-12-27
AU2013279021B2 (en) 2016-09-08
DK2861608T3 (da) 2019-06-24
US8901105B2 (en) 2014-12-02
EP2861608B1 (en) 2019-04-24
EA028136B1 (ru) 2017-10-31
NZ702695A (en) 2015-10-30
BR122021020778B1 (pt) 2022-07-12
KR101720885B1 (ko) 2017-03-28
BR112014031635A2 (pt) 2017-06-27
SI2861608T1 (sl) 2019-08-30
HUE043836T2 (hu) 2019-09-30
EA201492127A1 (ru) 2015-06-30
CA2875916A1 (en) 2013-12-27
JP6085026B2 (ja) 2017-02-22
SG11201408100YA (en) 2015-01-29
CY1122006T1 (el) 2020-10-14
HK1208226A1 (en) 2016-02-26
JP2015521617A (ja) 2015-07-30
JP2017105758A (ja) 2017-06-15
PT2861608T (pt) 2019-06-28
BR112014031635B1 (pt) 2022-01-11
AU2013279021C1 (en) 2017-03-16
MX2014015855A (es) 2015-03-05
HRP20190980T1 (hr) 2019-08-23
PH12014502823A1 (en) 2015-02-02

Similar Documents

Publication Publication Date Title
IN2014KN02915A (no)
IN2014MN01755A (no)
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
MX368504B (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MY188960A (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
MX2011011083A (es) Compuestos heterociclicos como inhibidores de mek.
EA030383B9 (ru) Бициклически замещённые урацилы, способы их получения, их применение, лекарственное средство и способ лечения с их применением
NZ719169A (en) Heteroaryl butanoic acid derivatives as lta4h inhibitors
GEP20156346B (en) Imidazole derivatives as pde10a enzyme inhibitors
MX2014003376A (es) Derivados de acido benzoico como inhibidores eif4e.
NZ592429A (en) PHENANTHROINDOLIZIDINE DERIVATIVE AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT
GEP20166481B (en) (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors
MX2014008864A (es) Derivados de triazolo[4,5-d]pirimidina.
NZ592392A (en) PHENANTHROINDOLIZIDINE COMPOUND AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT
NZ596527A (en) Nitrile derivatives and their pharmaceutical use and compositions
TN2012000242A1 (en) Heterocyclic sulfonamide derivatives
IN2015DN01329A (no)
IN2014DN00123A (no)
EA201300408A1 (ru) Производные фенилхиназолина
BR112012018658A2 (pt) sais farmaceuticamente aceitáveis de derivados heterocíclicos nitrogenosos - pirrolo, processo de preração e seu uso médico
MX2016001934A (es) Derivados de ciclopentilamina 3-sustituidos.
NZ624870A (en) Therapeutic agent for arthrosis
NZ622469A (en) Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof